A Prospective Observational Study of 1st and 2nd Line Vectibix Use in KRAS/NRAS-wt mCRC Patients to Evaluate Pattern of Use and Overall Response Rates
Phase of Trial: Phase IV
Latest Information Update: 23 Jun 2017
At a glance
- Drugs Panitumumab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms VISION
- Sponsors Amgen
- 14 Jun 2017 Planned End Date changed from 1 Jul 2018 to 30 Dec 2018.
- 14 Jun 2017 Planned primary completion date changed from 1 Jul 2018 to 30 Dec 2018.
- 10 Jun 2017 Biomarkers information updated